{"id":55531,"date":"2026-01-26T21:32:11","date_gmt":"2026-01-26T13:32:11","guid":{"rendered":"https:\/\/flcube.com\/?p=55531"},"modified":"2026-01-26T21:32:12","modified_gmt":"2026-01-26T13:32:12","slug":"sanofis-amlitelimab-hits-phase-iii-goals-in-atopic-dermatitis-targets-q4w-q12w-dosing-edge","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55531","title":{"rendered":"Sanofi\u2019s Amlitelimab Hits Phase\u202fIII Goals in Atopic Dermatitis, Targets Q4W\/Q12W Dosing Edge"},"content":{"rendered":"\n<p><strong>Sanofi<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ:\u202fSNY<\/a>) announced positive results from two global <strong>Phase\u202fIII studies (SHORE and COAST\u202f2)<\/strong> for <strong>amlitelimab<\/strong>, a <strong>fully human, non\u2011T cell\u2011depleting monoclonal antibody targeting OX40 ligand (OX40L)<\/strong>, demonstrating efficacy in patients aged <strong>12 years and older with moderate\u2011to\u2011severe atopic dermatitis (AD)<\/strong>. The company plans <strong>global regulatory filings in H2\u202f2026<\/strong>, positioning the asset as a <strong>conveniently dosed<\/strong> competitor to existing biologics.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-milestone\">Clinical Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Sanofi (NASDAQ:\u202fSNY)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Amlitelimab (anti\u2011OX40L monoclonal antibody)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Non\u2011T cell\u2011depleting, targets OX40 ligand to modulate T\u2011cell activation<\/td><\/tr><tr><td><strong>Studies<\/strong><\/td><td>SHORE and COAST\u202f2 (Phase\u202fIII)<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>Patients aged \u226512 years with moderate\u2011to\u2011severe atopic dermatitis<\/td><\/tr><tr><td><strong>Primary Endpoints<\/strong><\/td><td>vIGA\u2011AD 0\/1 with \u22652\u2011point reduction; EASI\u201175<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>Positive topline results announced<\/td><\/tr><tr><td><strong>Next Milestones<\/strong><\/td><td>AQUA and ESTUARY studies (H2\u202f2026); Global filings H2\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> <strong>OX40 ligand (OX40L)<\/strong> \u2013 a key co\u2011stimulatory molecule driving T\u2011cell\u2011mediated inflammation in AD<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> <strong>Non\u2011T cell\u2011depleting<\/strong> mechanism preserves immune function while dampening pathogenic T\u2011cell responses<\/li>\n\n\n\n<li><strong>Dosing Advantage:<\/strong> Demonstrated efficacy with <strong>every\u20114\u2011weeks (Q4W)<\/strong> and <strong>every\u201112\u2011weeks (Q12W)<\/strong> regimens, offering <strong>superior convenience<\/strong> vs. bi\u2011weekly or monthly competitors<\/li>\n\n\n\n<li><strong>Clinical Rationale:<\/strong> Addresses <strong>type\u202f2 inflammation<\/strong> upstream, potentially offering <strong>durable disease modification<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-phase-iii-results\">Clinical Evidence \u2013 Phase\u202fIII Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Amlitelimab Q4W<\/th><th>Amlitelimab Q12W<\/th><th>Placebo<\/th><th>Study<\/th><\/tr><\/thead><tbody><tr><td><strong>vIGA\u2011AD 0\/1 + \u22652\u2011point reduction<\/strong><\/td><td><strong>28.7%<\/strong><\/td><td><strong>32.3%<\/strong><\/td><td>16.8%<\/td><td>SHORE<\/td><\/tr><tr><td><strong>EASI\u201175<\/strong><\/td><td><strong>48.1%<\/strong><\/td><td><strong>46.8%<\/strong><\/td><td>32.3%<\/td><td>SHORE<\/td><\/tr><tr><td><strong>vIGA\u2011AD 0\/1 + \u22652\u2011point reduction<\/strong><\/td><td><strong>25.3%<\/strong><\/td><td><strong>25.7%<\/strong><\/td><td>14.8%<\/td><td>COAST\u202f2<\/td><\/tr><tr><td><strong>EASI\u201175<\/strong><\/td><td><strong>41.8%<\/strong><\/td><td><strong>40.5%<\/strong><\/td><td>24.2%<\/td><td>COAST\u202f2<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Efficacy:<\/strong> Both dosing regimens demonstrated <strong>statistically significant improvements<\/strong> across primary and key secondary endpoints vs. placebo<\/li>\n\n\n\n<li><strong>Consistency:<\/strong> Results replicated across two independent Phase\u202fIII trials (SHORE and COAST\u202f2)<\/li>\n\n\n\n<li><strong>Safety:<\/strong> Profile consistent with prior studies; <strong>non\u2011T cell\u2011depleting<\/strong> mechanism supports favorable immunologic safety<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-competitive-landscape\">Market Impact &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>Global AD Biologics Market<\/strong><\/td><td>$18.5\u202fbillion<\/td><td>$22.3\u202fbillion<\/td><td>$26.8\u202fbillion<\/td><\/tr><tr><td><strong>Moderate\u2011to\u2011Severe AD Patients (Global)<\/strong><\/td><td>65\u202fmillion<\/td><td>67\u202fmillion<\/td><td>69\u202fmillion<\/td><\/tr><tr><td><strong>Injectable Biologic Penetration<\/strong><\/td><td>28%<\/td><td>32%<\/td><td>36%<\/td><\/tr><tr><td><strong>Amlitelimab Peak Share<\/strong><\/td><td>0%<\/td><td>4%<\/td><td>8%<\/td><\/tr><tr><td><strong>Annual Treatment Cost (USD)<\/strong><\/td><td>\u2013<\/td><td>$35,000<\/td><td>$32,000<\/td><\/tr><tr><td><strong>Sanofi Revenue (Amlitelimab)<\/strong><\/td><td>\u2013<\/td><td>$890\u202fmillion<\/td><td>$2.1\u202fbillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dupixent<\/strong> (dupilumab, Sanofi\/Regeneron) \u2013 IL\u20114\/IL\u201113 inhibitor, market leader (Q2W dosing)<\/li>\n\n\n\n<li><strong>Adbry<\/strong> (tralokinumab, Leo Pharma) \u2013 IL\u201113 inhibitor (Q2W)<\/li>\n\n\n\n<li><strong>Rinvoq<\/strong> (upadacitinib, AbbVie) \u2013 Oral JAK inhibitor<\/li>\n\n\n\n<li><strong>Amlitelimab<\/strong> \u2013 <strong>First OX40L inhibitor<\/strong> with <strong>Q12W dosing option<\/strong>, potentially improving adherence and reducing healthcare burden<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dosing Differentiation:<\/strong> Q12W regimen represents <strong>longest interval<\/strong> among AD biologics, addressing <strong>patient preference for convenience<\/strong> and <strong>healthcare system cost savings<\/strong> (fewer clinic visits)<\/li>\n\n\n\n<li><strong>Pipeline Synergy:<\/strong> Complements Sanofi\u2019s <strong>immunology franchise<\/strong> alongside Dupixent; potential for <strong>combination therapy<\/strong> or <strong>sequential use<\/strong> in non\u2011responders<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> Leverages existing Sanofi biologics infrastructure; <strong>pre\u2011filled syringe\/autoinjector<\/strong> presentation planned for commercial launch<\/li>\n\n\n\n<li><strong>Global Launch:<\/strong> H2\u202f2026 filings target <strong>US, EU, and Japan<\/strong> simultaneously; <strong>pediatric indication<\/strong> (\u226512 years) expands addressable market vs. adult\u2011only competitors<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory filing timelines, commercial forecasts, and competitive positioning for amlitelimab. Actual results may differ due to regulatory review outcomes, AQUA\/ESTUARY study results, and market access dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi (NASDAQ:\u202fSNY) announced positive results from two global Phase\u202fIII studies (SHORE and COAST\u202f2) for amlitelimab,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,17,867,147],"class_list":["post-55531","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-clinical-trial-results","tag-nasdaq-sny","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanofi\u2019s Amlitelimab Hits Phase\u202fIII Goals in Atopic Dermatitis, Targets Q4W\/Q12W Dosing Edge - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sanofi (NASDAQ:\u202fSNY) announced positive results from two global Phase\u202fIII studies (SHORE and COAST\u202f2) for amlitelimab, a fully human, non\u2011T cell\u2011depleting monoclonal antibody targeting OX40 ligand (OX40L), demonstrating efficacy in patients aged 12 years and older with moderate\u2011to\u2011severe atopic dermatitis (AD). The company plans global regulatory filings in H2\u202f2026, positioning the asset as a conveniently dosed competitor to existing biologics.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55531\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi\u2019s Amlitelimab Hits Phase\u202fIII Goals in Atopic Dermatitis, Targets Q4W\/Q12W Dosing Edge\" \/>\n<meta property=\"og:description\" content=\"Sanofi (NASDAQ:\u202fSNY) announced positive results from two global Phase\u202fIII studies (SHORE and COAST\u202f2) for amlitelimab, a fully human, non\u2011T cell\u2011depleting monoclonal antibody targeting OX40 ligand (OX40L), demonstrating efficacy in patients aged 12 years and older with moderate\u2011to\u2011severe atopic dermatitis (AD). The company plans global regulatory filings in H2\u202f2026, positioning the asset as a conveniently dosed competitor to existing biologics.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55531\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-26T13:32:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-26T13:32:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55531#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55531\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi\u2019s Amlitelimab Hits Phase\u202fIII Goals in Atopic Dermatitis, Targets Q4W\\\/Q12W Dosing Edge\",\"datePublished\":\"2026-01-26T13:32:11+00:00\",\"dateModified\":\"2026-01-26T13:32:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55531\"},\"wordCount\":499,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Clinical trial results\",\"NASDAQ: SNY\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55531#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55531\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55531\",\"name\":\"Sanofi\u2019s Amlitelimab Hits Phase\u202fIII Goals in Atopic Dermatitis, Targets Q4W\\\/Q12W Dosing Edge - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-26T13:32:11+00:00\",\"dateModified\":\"2026-01-26T13:32:12+00:00\",\"description\":\"Sanofi (NASDAQ:\u202fSNY) announced positive results from two global Phase\u202fIII studies (SHORE and COAST\u202f2) for amlitelimab, a fully human, non\u2011T cell\u2011depleting monoclonal antibody targeting OX40 ligand (OX40L), demonstrating efficacy in patients aged 12 years and older with moderate\u2011to\u2011severe atopic dermatitis (AD). The company plans global regulatory filings in H2\u202f2026, positioning the asset as a conveniently dosed competitor to existing biologics.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55531#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55531\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55531#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi\u2019s Amlitelimab Hits Phase\u202fIII Goals in Atopic Dermatitis, Targets Q4W\\\/Q12W Dosing Edge\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi\u2019s Amlitelimab Hits Phase\u202fIII Goals in Atopic Dermatitis, Targets Q4W\/Q12W Dosing Edge - Insight, China&#039;s Pharmaceutical Industry","description":"Sanofi (NASDAQ:\u202fSNY) announced positive results from two global Phase\u202fIII studies (SHORE and COAST\u202f2) for amlitelimab, a fully human, non\u2011T cell\u2011depleting monoclonal antibody targeting OX40 ligand (OX40L), demonstrating efficacy in patients aged 12 years and older with moderate\u2011to\u2011severe atopic dermatitis (AD). The company plans global regulatory filings in H2\u202f2026, positioning the asset as a conveniently dosed competitor to existing biologics.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55531","og_locale":"en_US","og_type":"article","og_title":"Sanofi\u2019s Amlitelimab Hits Phase\u202fIII Goals in Atopic Dermatitis, Targets Q4W\/Q12W Dosing Edge","og_description":"Sanofi (NASDAQ:\u202fSNY) announced positive results from two global Phase\u202fIII studies (SHORE and COAST\u202f2) for amlitelimab, a fully human, non\u2011T cell\u2011depleting monoclonal antibody targeting OX40 ligand (OX40L), demonstrating efficacy in patients aged 12 years and older with moderate\u2011to\u2011severe atopic dermatitis (AD). The company plans global regulatory filings in H2\u202f2026, positioning the asset as a conveniently dosed competitor to existing biologics.","og_url":"https:\/\/flcube.com\/?p=55531","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-26T13:32:11+00:00","article_modified_time":"2026-01-26T13:32:12+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55531#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55531"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi\u2019s Amlitelimab Hits Phase\u202fIII Goals in Atopic Dermatitis, Targets Q4W\/Q12W Dosing Edge","datePublished":"2026-01-26T13:32:11+00:00","dateModified":"2026-01-26T13:32:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55531"},"wordCount":499,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Clinical trial results","NASDAQ: SNY","Sanofi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55531#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55531","url":"https:\/\/flcube.com\/?p=55531","name":"Sanofi\u2019s Amlitelimab Hits Phase\u202fIII Goals in Atopic Dermatitis, Targets Q4W\/Q12W Dosing Edge - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-26T13:32:11+00:00","dateModified":"2026-01-26T13:32:12+00:00","description":"Sanofi (NASDAQ:\u202fSNY) announced positive results from two global Phase\u202fIII studies (SHORE and COAST\u202f2) for amlitelimab, a fully human, non\u2011T cell\u2011depleting monoclonal antibody targeting OX40 ligand (OX40L), demonstrating efficacy in patients aged 12 years and older with moderate\u2011to\u2011severe atopic dermatitis (AD). The company plans global regulatory filings in H2\u202f2026, positioning the asset as a conveniently dosed competitor to existing biologics.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55531#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55531"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55531#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi\u2019s Amlitelimab Hits Phase\u202fIII Goals in Atopic Dermatitis, Targets Q4W\/Q12W Dosing Edge"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55531"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55531\/revisions"}],"predecessor-version":[{"id":55533,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55531\/revisions\/55533"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}